Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Fantastic day of immuno-oncology talks and networking at this years' annual OCION Symposium!

On 7th June we welcomed 160 members of the Oxford Cancer Immuno-Oncology Network to the Mathematical Institute in Oxford for our annual in-person Symposium. 

It was an absolute pleasure and honour to welcome Professor Lieping Chen from Yale School of Medicine to deliver our Keynote talk on the immunology of non-inflamed cancer.  The other sessions featured talks grouped into the themes of:

 

The day was also filled with some fantastic posters, exhibition stands and plenty of opportunities to establish new interdisciplinary connections. Congratulations to our poster prize winner and runner up Lea Cohen and Delaney Dominey-Foy!

OCION's Founding Director Professor Tim Elliott said:

 

What an action packed day showcasing the incredible interdisciplinary immuno-oncology work going on across Oxford! A huge thank you to all of our presenters, patient representatives, sponsors, poster judges, chairs and the operations team who made the Symposium such a great event.
- Tim Elliott

If you are a member of the University of Oxford and Oxford University Hospitals Trust and would like to join OCION mailing list to hear more about future events and funding calls, please email elizabeth.mann@medsci.ox.ac.uk.  

Similar Stories

OCION: In conversation with Dave Withers

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor David Withers, who recently moved to Oxford, to discuss his research.